If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
58
results.
Updated on
29/08/2025 [07:31:00]
Absstract of: US2025270618A1
Provided herein are methods for diagnosing and treating Alzheimer's disease in a subject comprising determining the expression level of three, four or five members of a panel of proteins in a biological sample obtained from the subject.
Absstract of: CN119998661A
In a first aspect, the present invention relates to a method for identifying a subject suffering from or at risk of developing Alzheimer's dementia (AD), the method comprising: (a) determining in a first bodily fluid sample of the subject at least an amount of a compound having a mass of 110.0367 in grams/mole; (b) determining an amount of the same compound as in (a) in a second body fluid sample of the subject; (c) determining a change in the amount of the compound determined according to (a) compared to the corresponding amount of the compound determined according to (b); (d) analyzing the change determined in (c) using a computer-implemented prediction algorithm capable of predicting AD in the subject based on the compound, thereby identifying a subject having AD or at risk of developing Alzheimer's dementia if AD is predicted; wherein the first body fluid sample is obtained prior to administration of thietherazine or a pharmaceutically acceptable salt thereof, and the second body fluid sample is obtained after administration of thietherazine or a pharmaceutically acceptable salt thereof to the subject.
Absstract of: US2025264482A1
The present specification discloses a composition, a system, and a method for predicting or diagnosing Alzheimer's disease, comprising a detecting agent of a B cell receptor clonotype specific to an Alzheimer's disease patient, and the composition according to one aspect of the present invention has an excellent effect in predicting or diagnosing Alzheimer's disease by simply using peripheral blood mononuclear cells isolated from a subject, in addition to methods such as MRI and PET scans using radioactive substances, by comprising a detecting agent of a B cell receptor (BCR) clonotype specific to an Alzheimer's disease patient.
Absstract of: US2025262247A1
The disclosure provides methods and compositions related to microglial cell development and therapies in neuronal development.
Absstract of: US2025262337A1
A method for detecting soluble oligomeric amyloid β in a subject is provided.
Absstract of: CN119768689A
Use of a novel highly toxic amyloid oligomer A beta o * 3F as a target for diagnosis of early and mid-advanced Alzheimer's disease (AD) and AD-derived mild cognitive impairment (MCI), A beta o * 3F is specifically bound by a 3F antibody, and exists in cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and AD-derived MCI patients, the Abeta oligomers have the advantages that the Abeta oligomers are high-toxicity oligomers, the levels of the Abeta oligomers are remarkably different in CSF, blood and/or brain tissues of AD patients, MCI patients and healthy old people, and the Abeta oligomers are super-toxicity oligomers, are the most major toxic components in A beta oligomer mixtures, have strong pathogenic effects and play a key role in occurrence and development of AD.
Absstract of: WO2025166920A1
The present invention belongs to the technical field of detection reagents, and relates to a modified polypeptide and the use thereof. The modified β amyloid protein polypeptide comprises peptide fragment I, peptide fragment II, and peptide fragment III located between the peptide fragment I and the peptide fragment II. The peptide fragment I contains a sequence as shown in SEQ ID NO: 9, the peptide fragment II contains a sequence as shown in SEQ ID NO: 18, and the peptide fragment III is composed of non-hydrophobic amino acids. Linker compounds are added between the peptide fragment I and the peptide fragment III, as well as between the peptide fragment II and the peptide fragment III. Compared with the original polypeptide, the modified polypeptide is reduced in terms of synthesis difficulty and cost, and improved in terms of stability. In terms of reaction activity with antibodies, the modified form is consistent with the original polypeptide, is a better raw material form for a calibrator of a diagnostic reagent, and is beneficial to development and wide application of a detection kit.
Absstract of: US2025257124A1
The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
Absstract of: US2025258184A1
The present disclosure belongs to the field of biological detection, and particularly relates to a protein antigen combination for detection of Alzheimer's disease (AD) and application thereof. The specific technical solution is as follows: An antigen combination is provided, wherein the antigen combination at least simultaneously includes the following proteins: DOC2A, LGALS1, KDM4D, and ADARB1. The present disclosure provides several new protein antigens and the combination thereof, which can be used for early-screening detection or diagnosis of AD, and are particularly suitable for risk assessment and prediction prior to the onset of AD. Meanwhile, the protein antigens and the combination thereof can distinguish AD from other types of dementia, and can be further prepared into related reagents or kits according to needs.
Absstract of: US2025257318A1
The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.
Absstract of: US2024197682A1
A method of inhibiting propagation of protein misfolding associated with a neurological disease, is carried out by contacting an environment populated with a propagating amyloid conformation of a protein (prion) associated with a neurological disease with molecules which binds multiple adjacent sites of the protein assemblies and allowing the molecules to bind multiple cites of the protein assemblies; and thereby impeding propagation of the disease-associated conformation of the protein in the environment. Drug/prion complexes are formed and uses of the drugs in detection and treatment of neurodegenerative diseases are disclosed.
Absstract of: AU2023357033A1
The present disclosure generally relates to the surprising discovery that subjects likely to respond to treatment with an 11β-HSD1 inhibitor can be selected for treatment based on a comparison between a baseline level of a tau protein in the subject, and a reference level of the tau protein.
Absstract of: AU2023356443A1
Provided is a protein marker Nell-1, which is present in a person's blood sample in an amount that is correlated with neurodegenerative disorders such as Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), and Parkinson's Disease (PD). Corresponding diagnostic and treatment methods for these neurodegenerative disorders as well as kits for diagnosing or treating the neurodegenerative disorders are also provided.
Absstract of: US2023213535A1
The present invention provides protein markers present in a person's blood sample (such as a plasma, serum, or whole blood sample) that are associated with the Alzheimer's Disease (AD), diagnostic and treatment methods for AD, and kits for diagnosing AD.
Absstract of: AU2023351193A1
Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
Absstract of: TW202438878A
The present disclosure provides a method of manufacturing a biosensor for detecting a biomarker of Alzheimer's disease, comprising steps of depositing an aluminum oxide film on a Si substrate by an atomic layer deposition system to form an Al2O3/Si substrate; depositing electrical contacts Cr/Au on the Al2O3/Si substrate by a thermal evaporator to form a source, a drain and a planar gate on the Al2O3/Si substrate; providing a bilayer graphene on the Al2O3/Si substrate by thermal annealing under a vacuum environment; providing a bilayer graphene to a low-damage plasma treatment (LDPT) with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite on the Al2O3/Si substrate; and immobilizing an antibody on a surface of the GO/G layered composite through a reaction between amine groups of the antibody and carboxyl groups of GO of the GO/G layered composites, wherein the antibody is specific for p-tau217 protein.
Absstract of: KR20250119690A
본 발명은 아밀로이드-베타로 유도된 알츠하이머병 동물모델과 이를 이용하여 알츠하이머병 치료제를 스크리닝하는 방법에 관한 것이다. 본 발명의 아밀로이드-베타로 유도된 알츠하이머병 제브라피쉬 동물모델은, 아밀로이드-베타 이외의 물질에 의해서도 인지장애를 일으키는 종래의 제브라피쉬를 활용한 동물모델과 달리, 아밀로이드-베타에 의해서만 알츠하이머병이 유도된다. 이에, 본 발명의 동물모델은 아밀로이드-베타에 의한 알츠하이머병 유발에 대한 재현성이 우수하다. 또한, 본 발명의 동물모델을 활용한 아밀로이드-베타와 관련된 질병 치료제의 스크리닝 방법은, 아밀로이드-베타로 인해 유발된 질환의 치료제를 정확하고 편리하게 스크리닝할 수 있어, 이와 관련된 신약 개발에 유용하다.
Absstract of: US2025250539A1
A method for evaluating activity of a test substance for inhibiting or promoting aggregation of aggregating proteins is provided. The method includes culturing cells in the presence of aggregating proteins labeled with a label and a test substance, thereby forming a cell culture and quantifying aggregated and/or deposited aggregating proteins on a surface of the cells and/or in the cells in the cell culture with the use of the label as an indicator.
Absstract of: WO2025165672A1
Provided herein are systems and methods for a rapid microfluidic in vivo bioassay for evaluating the cognitive health benefits of compounds.
Absstract of: US2025251407A1
A monoclonal antibody composition comprises a capture antibody AB7G and a detection antibody AB11A2 for using in preparation of a kit for quantitative detection of amyloid in human body fluids, and the antibodies are monoclonal antibodies secreted by cultured hybridoma cells. The kit specifically recognizes an Aβ42 oligomer, with a linear detection range of 3.9-125 pg/mL, and a lowest detection limit of 7.8 pg/mL. A core technique for kit assembly lies in that the monoclonal antibody AB7G is fixed on a microplate to serve as the capture antibody, and the monoclonal antibody AB11A2 is labeled and then diluted at 1:2000 to serve as the detection antibody. Meanwhile, the present invention relates to heavy and light chain variable region genes of the monoclonal antibodies AB7G and AB11A2 and peptides encoded thereby.
Absstract of: EP4597103A1
The objective of the present invention is to provide a method for screening for a substance having activity of inhibiting or promoting aggregation of aggregating proteins. More specifically, the present invention relates to a method for evaluating activity of a test substance for inhibiting or promoting aggregation of aggregating proteins comprising: a step of culturing cells in the presence of aggregating proteins labeled with a label and a test substance; and a step of quantifying the aggregated and/or deposited aggregating proteins on the cell surface and/or in the cells in the cell culture product with the use of the label as the indicator.
Absstract of: AU2023351193A1
Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
Absstract of: WO2024069193A1
The invention relates to methods of screening for the presence of proteopathies, to methods of diagnosing proteopathies, to methods of differentially diagnosing proteopathies, to methods of assessing the severity, stage and/or prognosis of proteopathies, and to methods for monitoring the progression of proteopathies. The invention also relates to methods for determining the efficacy of therapeutic interventions for proteopathies.
Absstract of: WO2024014834A1
The present invention relates to a biomarker for the early diagnosis of Alzheimer's disease and a use thereof, and more particularly, the present invention relates to: a biomarker composition for the early diagnosis of Alzheimer's disease, the biomarker composition comprising one or more genes selected from the group consisting of alpha-2-macroglobulin (A2M), creatine kinase M-type (CKM), filamin-A (FLNA), integral alpha-IIb (ITGA2B), alpha-1-acid glycoprotein 2 (ORM2), phospholipid transfer protein (PLTP), haptoglobin (HP), sulfhydryl oxidase 1 (QSOX1), protein-glutamine gamma-glutamyltransferase 2 (TGM2), filamin C (FLNC), heat shock protein 70 (HSP70) and lysomal alpha-mannosidase (heat shock protein MAN2B1), or a protein expressed from the genes; a method for the early diagnosis of Alzheimer's disease; a diagnostic kit for the early diagnosis of Alzheimer's disease; and a method for providing information for predicting and diagnosing Alzheimer's disease.
Nº publicación: MX2025008034A 01/08/2025
Applicant:
MABWELL THERAPEUTICS INC [US]
MABWELL THERAPEUTICS, INC
Absstract of: MX2025008034A
The present disclosure provides anti-amyloid β (Aβ) antibodies and antibody fragments that preferentially bind soluble amyloid Aβ protofibril/oligomer and trigger ADPC in microglial cells, anti-amyloid β (Aβ) antibodies and antibody fragments that reduce soluble amyloid Aβ protofibril/oligomer levels and insoluble amyloid Aβ plaque in brain tissue, and the use of anti-Aβ protofibril/oligomer antibodies and antibody fragments in therapy, prophylaxis, diagnosis, screening, and monitoring of conditions associated with Aβ protein aggregation, in particular Alzheimer's disease (AD).
BOPI
Electronic site
